Bio-Rad Provides Immunohematology Platforms to South African National Blood Service
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and the South African National Blood Service (SANBS) have announced that they have substantially completed the rollout of Bio-Rad’s IH-500 immunohematology systems across the SANBS network of transfusion medicine laboratories, as part of an exclusive agreement finalized in early 2022.
The IH-500 is a fully automated random-access platform for blood typing and screening, providing transfusion medicine labs with fast and reliable results in a 24/7 environment. In partnership with SANBS, Bio-Rad has to date successfully installed its IH-500 systems across the SANBS network of eighty-six labs and blood banks enabling high-quality and consistent lab testing across the provinces that rely on SANBS to provide blood products and services to South Africa’s citizens.
“The SANBS implementation was a complex project united by a shared purpose,” said Dara Wright, EVP, and President of Bio-Rad’s Clinical Diagnostics Group. “The Bio-Rad and SANBS partnership brings together a prominent provider of blood transfusion medicine with a leading provider of immunohematology products backed by a mission to deliver high-quality transfusion services to patients across South Africa.”
“We are delighted to partner with Bio-Rad and utilize its leading immunohematology platforms for compatibility testing”, said Marion Vermeulen, Executive Director of Transfusion Medicine, and Technical Services at SANBS. “We pride ourselves on being trusted to help save lives and now that we have Bio-Rad’s instruments, technical support, and scientific expertise on board, we are confident we can deliver on our mission to provide patients across South Africa with safe, high-quality blood transfusion products and medical services.”
BIO-RAD and IH-500 are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.